Glaucoma is the second leading cause of irreversible blindness worldwide. The major risk factor for most glaucoma patients — and the focus of treatment — is increased intraocular pressure (IOP). One factor that correlates with IOP rise is trabecular meshwork (TM) decellularization, which occurs naturally with age. Replacing lost TM cells using stem cells from the same region could restore healthy aqueous outflow and return IOP to normal, thereby slowing glaucoma progression and preserving vision.
